Breast cancer vaccine - NewLink Genetics

Drug Profile

Breast cancer vaccine - NewLink Genetics

Alternative Names: breast-cancer-vaccine-NewLink-Genetics; HyperAcute - Breast cancer vaccine; HyperAcute-breast-cancer-vaccine

Latest Information Update: 19 Apr 2012

Price : $50

At a glance

  • Originator NewLink Genetics Corporation
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.


Highest Development Phases

  • Discontinued Breast cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 18 Apr 2012 Discontinued - Phase-I/II for Breast cancer in USA (Intradermal)
  • 06 Jul 2006 NewLink Genetics terminates phase I/II trial in Breast cancer in the USA (NCT00090480)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top